- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07694050
Choosing an Access for Endovascular Treatment of Femoral-popliteal Segment Occlusions (ATFA)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The purpose of the study: to compare the complication rate of the shoulder and retrograde femoral access in elderly patients with occlusive lesions of the femoral-popliteal segment of the lower extremity arteries.
Scientific hypotheses:
- The shoulder access has a lower number of complications compared to the femoral access
- The shoulder access has a lower number of complications requiring surgical intervention compared to the femoral access
- The shoulder access has a comparable % of success of the main intervention with the femoral access Inclusion criteria: arterial diameter at the access site of at least 3 mm, indications for endovascular intervention on the lower extremity arteries, age of 60 years or more, and patient consent to participate in the study.
Exclusion criteria: inability to perform an access due to stenotic lesions of the above-mentioned arteries (common femoral, iliac, axillary, subclavian arteries, brachiocephalic trunk); height more than 180 cm; presence of concomitant pathology limiting the survival of patients; pathology of the blood coagulation system (hemophilia, thrombocytopathies, etc.), previously performed catheterization through the access artery.
The required sample size was calculated using the M. Blanda method [3] for a study with increased accuracy. The required level of significance (α) was 0.05, and the study's power was 95%. The estimated complication rates in the Femoral and Brachial groups were assumed to be 2% and 9%, respectively. Under these conditions, the estimated sample size was 269 patients. The planned loss rate during the study was 5%. Therefore, the minimum sample size was 283 patients.
The study has an experimental design and follows the CONSORT protocol. A simple method of randomization using a random number generator was selected.
The puncture of the brachial or common femoral artery was performed under ultrasound control. The choice of the type of arterial access was made by randomization using a random number generator, and depending on this choice, the patient was assigned to one of the groups: the Femoral access group or the Brachial access group. The femoral artery was catheterized at a typical location, and the brachial artery was catheterized 2-3 cm above the elbow. The choice of access location was made by randomization using the random number method, and the patient was assigned to one of the groups based on this choice. The following instruments were used to perform the intervention: an 18G angiographic needle 7 cm long, a 0.035-inch diagnostic guide 260 cm, a 6 Fr 90 cm guide introducer (Destination, manufacturer Terumo), 5 Fr diagnostic catheters 125 cm long (Optitorque, manufacturer Terumo or Impress, manufacturer Merit Medical), peripheral conductors 0.035 or 0.018 inches, balloon catheters with a delivery length of 150 cm and 180 cm (Atropos, manufacturer of BrosMed; Pacific Plus, manufacturer of Medtronic) and balloon catheters for peripheral arteries with a drug coating of paclitaxel and a delivery system length of 150 cm (Ranger, manufacturer of Boston Scientific). 5,000 IU of heparin in saline solution was injected into the catheterized artery. Hemostasis was achieved by applying a pressure bandage in the case of a shoulder access or by using a suturing device (AngioSeal, Terumo) in the case of a femoral access.
A control examination of the access site was performed within 3 hours after the end of the intervention, and then, if there were no complaints, the bandage was removed. After the bandage was removed, the patients underwent an ultrasound examination. Complications were recorded within 3 days after the intervention.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Moscow, Russland, 117513
- Central Clinical Hospital of St. Alexy Metropolitan of Moscow of the Moscow Patriarchate of the Russian Orthodox Church, Moscow
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion criteria: arterial diameter at the access site of at least 3 mm, indications for endovascular intervention on the lower extremity arteries, age of 60 years or more, and patient consent to participate in the study.
Exclusion criteria: inability to perform an access due to stenotic lesions of the above-mentioned arteries (common femoral artery, iliac arteries, axillary artery, subclavian artery, and brachiocephalic trunk); height exceeding 180 cm; presence of concomitant pathology that limits patient survival; coagulation system pathology (hemophilia, thrombocytopathies, etc.), and previous arterial access catheterizations.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Brachial
Brachial artery catheterization
|
The puncture of the brachial artery was performed under ultrasound guidance. The brachial artery was catheterized 2-3 cm above the elbow crease. The following instruments were used to perform the intervention: an 18G angiographic needle 7 cm long, a 0.035-inch diagnostic guide 260 cm, a 6 Fr 90 cm guide introducer (Destination, manufacturer Terumo), 5 Fr diagnostic catheters 125 cm long (Optitorque, manufacturer Terumo or Impress, manufacturer Merit Medical), peripheral conductors 0.035 or 0.018 inches, balloon catheters with a delivery length of 150 cm and 180 cm (Atropos, manufacturer of BrosMed; Pacific Plus, manufacturer of Medtronic) and balloon catheters for peripheral arteries with a drug coating of paclitaxel and a delivery system length of 150 cm (Ranger, manufacturer of Boston Scientific). 5000 IU of heparin in saline solution was injected into the catheterized artery. Hemostasis was achieved by applying a pressure bandage. The access site was inspected again 3 hours after th |
|
Experimental: Femoral
Femoral artery catheterization
|
The common femoral artery was punctured under ultrasound guidance. The femoral artery was catheterized at a typical site. The following instruments were used to perform the intervention: an 18G angiographic needle 7 cm long, a 0.035-inch diagnostic guide 260 cm, a 6 Fr 90 cm guide introducer (Destination, manufacturer Terumo), 5 Fr diagnostic catheters 125 cm long (Optitorque, manufacturer Terumo or Impress, manufacturer Merit Medical), peripheral conductors 0.035 or 0.018 inches, balloon catheters with a delivery length of 150 cm and 180 cm (Atropos, manufacturer of BrosMed; Pacific Plus, manufacturer of Medtronic) and balloon catheters for peripheral arteries with a drug coating of paclitaxel and a delivery system length of 150 cm (Ranger, manufacturer of Boston Scientific). 5000 IU of heparin in saline solution was injected into the catheterized artery. Hemostasis was performed using a suturing device (AngioSeal, Terumo) through the femoral access. The access site was inspected agai |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Hematoma at the access point
Zeitfenster: Within 72 hours after artery catheterization
|
Hematoma at the access point
|
Within 72 hours after artery catheterization
|
|
Acute artery occlusion
Zeitfenster: Within 72 hours after artery catheterization
|
Acute artery occlusion
|
Within 72 hours after artery catheterization
|
|
Post-catheterization aneurysm that required surgery
Zeitfenster: Within 72 hours after radial artery catheterization
|
Post-catheterization aneurysm that required surgery
|
Within 72 hours after radial artery catheterization
|
|
Technical success of access
Zeitfenster: Perioperative/Periprocedural
|
Technical success of access
|
Perioperative/Periprocedural
|
|
Technical success of the index procedure
Zeitfenster: Perioperative/Periprocedural
|
Technical success of the index procedure
|
Perioperative/Periprocedural
|
|
Conversion to another access
Zeitfenster: Perioperative/Periprocedural
|
Conversion to another access
|
Perioperative/Periprocedural
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Total number of complications
Zeitfenster: Within 72 hours after radial artery catheterization
|
Total number of complications
|
Within 72 hours after radial artery catheterization
|
|
Total number of complications that required surgery
Zeitfenster: Within 72 hours after radial artery catheterization
|
Total number of complications that required surgery
|
Within 72 hours after radial artery catheterization
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- 261
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brachial artery catheterization
-
Kanuni Sultan Suleyman Training and Research HospitalNoch keine RekrutierungUltraschall | HirndruckTürkei (türkiye)
-
Thomas Jefferson UniversityRekrutierungNicht-kleinzelliges Lungenkarzinom | Lungenkrebs im Stadium III AJCC v8 | Lungenkrebs im Stadium II AJCC v8 | Lungenkrebs im Stadium I AJCC v8Vereinigte Staaten
-
University of WuerzburgDeutsche Stiftung für HerzforschungUnbekanntStreicheln | Koronare Herzerkrankung | HirninfarktDeutschland
-
Hospital Privado de Comunidad de Mar del PlataRekrutierungGefäßerkrankungenArgentinien
-
University of LeipzigGerman Research Foundation; Baylor College of Medicine; University of Pennsylvania und andere MitarbeiterAktiv, nicht rekrutierendAortenaneurysma, thorakoabdominalSchweden, Niederlande, Deutschland, Frankreich, Polen, Schweiz, Österreich, Vereinigtes Königreich, Italien
-
Massachusetts General HospitalAbgeschlossenDiabetes Typ 1 | Typ 2 DiabetesVereinigte Staaten
-
Green Cross CorporationSymyooAbgeschlossen
-
Sansum Diabetes Research InstituteJuvenile Diabetes Research Foundation; Schneider Children's Medical Center,...AbgeschlossenDiabetes mellitus, Typ 1Vereinigte Staaten, Israel
-
Second Affiliated Hospital, School of Medicine,...RekrutierungPostherpetische Neuralgie | EsketaminChina
-
First Affiliated Hospital of Chongqing Medical...Noch keine RekrutierungDepression | Esketamin | ECT